Anti-Cancer MAbS Global Market Report 2025

Global Anti Cancer MAbS Market Report 2024

Anti-Cancer MAbS Global Market Report 2025 – By Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications), By End User (Hospitals, Research Institutes, Other End Users ) – Market Size, Trends, And Global Forecast 2025-2034

Name: Anti-Cancer MAbS Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Anti-Cancer MAbS Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Anti-Cancer MAbS Global Market Report 2025

Proud Members Of

Anti-Cancer MAbS Market Definition

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread.

The main types of anti-cancer mAbs are murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine refers to a type of monoclonal antibody (mAb) that is a laboratory-made copy of a single antibody, produced by a single B cell, derived from mice or rats, they are used to bind to a specific antigen. These are used in various applications such as blood cancer, breast cancer, lung cancer, Melanoma, colorectal cancer, liver cancer and others and are used in hospitals, research institutes, and others.

Anti-Cancer MAbS Market Segmentation

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes

2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes

3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes

4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats

Anti-Cancer MAbS Market Size and growth rate 2025 to 2029: Graph

Anti-Cancer MAbS Market Size 2025 And Growth Rate

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $69.33 billion in 2024 to $76.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.

Anti-Cancer MAbS Market Growth Forecast

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $109.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mAbs, global efforts to address cancer burden, expansion of patient access programs. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.

Book your 30 minutes free consultation with our research experts

Anti-Cancer MAbS Market Driver: Rising Global Cancer Prevalence Fuels Anticancer Monoclonal Antibodies (MABS) Market Growth

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system's own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in January 2022, according to PubMed, a US-based biomedical and life sciences journal, it is estimated that around 1.9 million new cancer cases are expected to be diagnosed globally, with 609,360 cancer deaths in the United States. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.

Anti-Cancer MAbS Market Driver: The Impact Of Increasing Clinical Trials On The Anticancer Monoclonal Antibodies (MABS) Market

The growing number of clinical trials is expected to propel the growth of the anti-cancer mAbs market going forward. A clinical trial is a research study that prospectively assigns people to one or more health-related interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials have played a crucial role in developing and refining anti-cancer monoclonal antibodies (mAbs) as a promising therapeutic approach to provide valuable insights into the safety, efficacy, and potential mechanisms of action of various mAbs. For instance, in May 2023, according to ClinicalTrials.gov, a platform for registering clinical trials, the total number of clinical trials reported 452,604 in 2023 an increase from 365,000 registered trials reported in 2021. Therefore, the growing demand for physical therapists is driving the growth of the anti-cancer mAbs market.

Global Anti-Cancer MAbS Market Major Players

Major companies operating in the anti-cancer mabs market include Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB

Global Anti-Cancer MAbS Market Trend: Product Innovations Drive Advancements In Anticancer Monoclonal Antibodies (MABS)

Product innovations are a key trend gaining popularity in the anticancer mAbs market. Major companies operating in the anticancer mAbs market are introducing more effective and targeted cancer treatments, such as mAbs drugs to strengthen their position in the market. For instance, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company launched PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a unique monoclonal antibody (mAb) combination treatment for HER2-positive early breast cancer. It is a subcutaneous (under the skin) injection that combines the two mAbs pertuzumab and trastuzumab with the enzyme hyaluronidase. The addition of hyaluronidase, an enzyme that helps to increase the absorption of the mAbs, allows the treatment to be given subcutaneously rather than intravenously.

Global Anti-Cancer MAbS Market Trend: Innovative Approaches In Anticancer Monoclonal Antibodies Market

Major companies operating in the anti-cancer mAbs market are focused on developing innovative solutions, such as clinical trials, to gain a competitive edge in the market. Clinical trials are research studies that evaluate new treatments, medications, or devices in human participants, helping to determine whether new interventions are safe and effective. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, launched the Phase I Trial of GD2-Targeted Radioimmunotherapy. The Phase 1 trial evaluates the safety and efficacy of GD2-SADA, pre-targeted radioimmunotherapy (RIT) for treating certain GD2-positive solid tumors, including small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA is a novel RIT that uses a two-step approach to deliver radiation to tumor cells. First, the SADA protein is administered, which binds to GD2, a protein found on the surface of many solid tumors. Next, the radioactive ligand 177Lu-DOTA is administered, which binds to the SADA protein and delivers radiation to the tumor cells. This two-step approach is designed to minimize radiation exposure to healthy tissues.

Anti-Cancer MAbS Market Merger And Acquisition: Merck's Acquisition of Prometheus Biosciences to Boost Immunology Portfolio

In June 2024, Merck & Co., Inc., a US-based pharmaceutical company acquired Prometheus Biosciences Inc. for $10.8 billion. With this acquisition, Merck enhances it portfolio in immunology, particularly with Prometheus's lead candidate, PRA023 (now known as MK-7240), a monoclonal antibody targeting TL1A, which is implicated in autoimmune diseases like ulcerative colitis and Crohn's disease. Prometheus Biosciences Inc. is a US-based clinical-stage biotechnology company that provides anti-cancer mAbS.

Regional Outlook For The Global Anti-Cancer MAbS Market

North America was the largest region in the anti-cancer MAbS market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-cancer mAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Cancer MAbS Market?

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Anti-Cancer MAbS Industry?

The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-Cancer MAbS Global Market Report 2024

Report Attribute	Details
Market Size Value In 2025	$76.92 billion
Revenue Forecast In 2034	$109.88 billion
Growth Rate	CAGR of 9.3% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types 2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications 3) By End User: Hospitals, Research Institutes, Other End Users Subsegments: 1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes 2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes 3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes 4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Anti-Cancer MAbS Market Characteristics

3. Anti-Cancer MAbS Market Trends And Strategies

4. Anti-Cancer MAbS Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anti-Cancer MAbS Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Cancer MAbS PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Anti-Cancer MAbS Market Growth Rate Analysis

5.4. Global Anti-Cancer MAbS Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Anti-Cancer MAbS Total Addressable Market (TAM)

6. Anti-Cancer MAbS Market Segmentation

6.1. Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Murine Antibodies

Chimeric Antibodies

Humanized Antibodies

Other Types

6.2. Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Blood Cancer

Breast Cancer

Lung Cancer

Melanoma

Colorectal Cancer

Liver Cancer

Other Applications

6.3. Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Research Institutes

Other End Users

6.4. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Murine IgG

Murine IgM

Other Murine Isotypes

6.5. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chimeric IgG

Chimeric IgM

Other Chimeric Isotypes

6.6. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Humanized IgG

Humanized IgM

Other Humanized Isotypes

6.7. Global Anti-Cancer MAbS Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fully Human Antibodies

Bispecific Antibodies

Conjugated Antibodies

Other Novel Formats

7. Anti-Cancer MAbS Market Regional And Country Analysis

7.1. Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Cancer MAbS Market

8.1. Asia-Pacific Anti-Cancer MAbS Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Cancer MAbS Market

9.1. China Anti-Cancer MAbS Market Overview

9.2. China Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Cancer MAbS Market

10.1. India Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Cancer MAbS Market

11.1. Japan Anti-Cancer MAbS Market Overview

11.2. Japan Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Cancer MAbS Market

12.1. Australia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Cancer MAbS Market

13.1. Indonesia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Cancer MAbS Market

14.1. South Korea Anti-Cancer MAbS Market Overview

14.2. South Korea Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Cancer MAbS Market

15.1. Western Europe Anti-Cancer MAbS Market Overview

15.2. Western Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Cancer MAbS Market

16.1. UK Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Cancer MAbS Market

17.1. Germany Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Cancer MAbS Market

18.1. France Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Cancer MAbS Market

19.1. Italy Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Cancer MAbS Market

20.1. Spain Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Cancer MAbS Market

21.1. Eastern Europe Anti-Cancer MAbS Market Overview

21.2. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Cancer MAbS Market

22.1. Russia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Cancer MAbS Market

23.1. North America Anti-Cancer MAbS Market Overview

23.2. North America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Cancer MAbS Market

24.1. USA Anti-Cancer MAbS Market Overview

24.2. USA Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Cancer MAbS Market

25.1. Canada Anti-Cancer MAbS Market Overview

25.2. Canada Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Cancer MAbS Market

26.1. South America Anti-Cancer MAbS Market Overview

26.2. South America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Cancer MAbS Market

27.1. Brazil Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Cancer MAbS Market

28.1. Middle East Anti-Cancer MAbS Market Overview

28.2. Middle East Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Cancer MAbS Market

29.1. Africa Anti-Cancer MAbS Market Overview

29.2. Africa Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Cancer MAbS Market Competitive Landscape And Company Profiles

30.1. Anti-Cancer MAbS Market Competitive Landscape

30.2. Anti-Cancer MAbS Market Company Profiles

30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Cancer MAbS Market Other Major And Innovative Companies

31.1. Johnson & Johnson

31.2. Novartis AG

31.3. Merck & Co. Inc.

31.4. Spectrum Pharmaceuticals Inc.

31.5. AstraZeneca plc.

31.6. Pfizer Inc.

31.7. Gilead Sciences Inc.

31.8. Bayer HealthCare

31.9. ImmunoGen Inc.

31.10. Genentech Inc.

31.11. AbbVie Inc.

31.12. Takeda Pharmaceuticals

31.13. Seattle Genetics

31.14. Regeneron Pharmaceuticals

31.15. Celgene

32. Global Anti-Cancer MAbS Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Cancer MAbS Market

34. Recent Developments In The Anti-Cancer MAbS Market

35. Anti-Cancer MAbS Market High Potential Countries, Segments and Strategies

35.1 Anti-Cancer MAbS Market In 2029 - Countries Offering Most New Opportunities

35.2 Anti-Cancer MAbS Market In 2029 - Segments Offering Most New Opportunities

35.3 Anti-Cancer MAbS Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Amgen Inc. Financial Performance

Table 79: Bristol Myers Squibb Company Financial Performance

Table 80: Eli Lilly and Company Financial Performance

Table 81: F. Hoffmann-La Roche Ltd. Financial Performance

Table 82: GlaxoSmithKline plc Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Anti-Cancer MAbS Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Amgen Inc. Financial Performance

Figure 79: Bristol Myers Squibb Company Financial Performance

Figure 80: Eli Lilly and Company Financial Performance

Figure 81: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 82: GlaxoSmithKline plc Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the regenerative medicine market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the gynecology drugs market research report 2022 with industry size, share, segments and market growth

Pain Management Devices And Therapies Global Market Report 2025 – By Type (Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps), By Neurostimulation Devices (Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices), By Electrical Stimulation Devices (Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS), By Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), By Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Metabolomics Global Market Report 2025 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2025 – By Product (Instrument, Reagent), By Technology (NASBA, HAD), By Application (Blood Screening, Infectious Disease Diagnostics, Cancer), By End-User (Hospital, Reference Laboratories, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Monoclonal Antibodies (MAs) Global Market Report 2025 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cancer biologics Global Market Report 2025 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications), By Distribution Channel (Hospitals, Clinics, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Skin Cancer Drugs Global Market Report 2025 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs), By End Users (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pancreatic Cancer Drugs Global Market Report 2025 – By Type (Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs), By Drug Combination (Single, Double, Triplet, Quadruplet), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Lung Cancer Drugs Global Market Report 2025 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Anti-Cancer MAbS Global Market Report 2024 market?

How will the Anti-Cancer MAbS Global Market Report 2024 market drivers and restraints affect the market dynamics? What forces will shape the Anti-Cancer MAbS Global Market Report 2024 industry going forward?

The Anti-Cancer MAbS Global Market Report 2024 market major growth driver - The Impact Of Increasing Clinical Trials On The Anticancer Monoclonal Antibodies (MABS) Market. For further insights on the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here

What is the forecast market size or the forecast market value of the Anti-Cancer MAbS Global Market Report 2024 market?

The Anti-Cancer MAbS Global Market Report 2024 market size has grown strongly in recent years. The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $69.33 billion in 2024 to $76.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand. The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $109.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mAbs, global efforts to address cancer burden, expansion of patient access programs. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies. For further insights on the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here

How is the Anti-Cancer MAbS Global Market Report 2024 market segmented?

The anti-cancer mabs market covered in this report is segmented –
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes
2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes
3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes
4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats For further insights on the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here

Which region has the largest share of the Anti-Cancer MAbS Global Market Report 2024 market? What are the other regions covered in the report?

North America was the largest region in the anti-cancer MAbS market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here.

Who are the major players in the Anti-Cancer MAbS Global Market Report 2024 market?

What are the key trends in the Anti-Cancer MAbS Global Market Report 2024 market?

Major trends in the Anti-Cancer MAbS Global Market Report 2024 market include Innovative Approaches In Anticancer Monoclonal Antibodies Market. For further insights on the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here.

What are the major opportunities in the Anti-Cancer MAbS Global Market Report 2024 market? What are the strategies for the Anti-Cancer MAbS Global Market Report 2024 market?

For detailed insights on the major opportunities and strategies in the Anti-Cancer MAbS Global Market Report 2024 market, request a sample here.

How does the Anti-Cancer MAbS Global Market Report 2024 market relate to the overall economy and other similar markets?

For detailed insights on Anti-Cancer MAbS Global Market Report 2024's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Anti-Cancer MAbS Global Market Report 2024 industry?

For detailed insights on the mergers and acquisitions in the Anti-Cancer MAbS Global Market Report 2024 industry, request a sample here.

What are the key dynamics influencing the Anti-Cancer MAbS Global Market Report 2024 market growth? SWOT analysis of the Anti-Cancer MAbS Global Market Report 2024 market.

For detailed insights on the key dynamics influencing the Anti-Cancer MAbS Global Market Report 2024 market growth and SWOT analysis of the Anti-Cancer MAbS Global Market Report 2024 industry, request a sample here.